Chugai says it is building facilities that will give it the largest
bioreactor capacity for biologicals production - at 85,000L - of
any company in the world by 2007.
DPS Engineering, an Irish engineering firm which specialises in
providing services to the pharmaceutical sector says it is planning
to create 250 jobs over the next five years as it continues a major
growth phase in its business in...
Troubled chemicals group Rhodia sees its CEO depart as the company
announces another restructuring round that will see €600m in
divestments by end-2004.
Cardinal Health is to acquire 100 per cent ownership of protein
production specialist Gala Biotech for $15.5 million (€13.2m)in a
move to bolster its drug development services business.
Degussa and Shionogi set up a new joint venture company in Japan to
sell precipitated silica, silica gel and matting agents, used as
pharmaceutical additives.
Germany's Bayer has continued the revamp of its business units by
setting up its chemicals, technology services and healthcare
activities as three separate legal entities. The move follows the
carve-out of Bayer CropScience a...
Pharmaceutical major GlaxoSmithKline has set aside £1 million
(€1.4m) to soften the blow of selling its bulk active ingredient
manufacturing facility in Montrose.
Boehringer Ingelheim doubles its biopharmaceutical production
capacity at a stroke with the completion of a new plant at its site
in Biberach, Germany; a similar expansion in Austria is also
underway.
A new report has suggested that an average-sized, top 20 drug
company only needs to produce two new products every three years to
maintain growth rates.
The axe looks set to fall on Scottish biotechnology company PPL
Therapeutics now that the company put itself up for sale, having
failed to convince investors of a rescue plan.
Recordati is expecting to sell off its pharmaceutical chemical
operations by the end of next year or early in 2004, according to
the company's chief executive, who expects €80-€90m in proceeds for
the sale.
Millions of dollars are being spent unnecessarily each year on
treatments for high blood pressure says research published this
week in BMC Health Services Research.
The creditors of Australian over-the-counter medicines and vitamins
manufacturer Pan Pharmaceuticals have rejected a rescue bid for the
company at a meeting held last week. Another meeting is due to be
held later today.
Chiron's headquarters is hit by two homemade bombs, with an animal
rights group claiming responsibility. The blasts caused no
casualties and only minor damage to property, but represent an
alarming escalation in the tactics used...
French company Flamel Technologies has added another high-profile
client for its drug delivery technology spurring another leap in
its shares that have already climbed almost 800 per cent over the
last 12 months.
Schering-Plough has lowered its financial forecasts for the second
time and unveiled a fresh round of cost cutting in an attempt to
stabilise its finances.
Degussa follows its peers in the speciality chemicals industry by
posting weak interim results held back by currency factors, raw
material costs and lower demand.
BASF, the world's largest chemicals company, has said that it will
expand an ongoing restructuring program in North America after
reporting lower-than-expected second-quarter sales and profits.
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Cambrex plans to sell off its Rutherford Chemicals business for $64
million (€56m) to allow it to focus on its human health and
biosciences activities.
Italy's Recordati has said that it plans to sell off its
pharmaceutical chemical activities over the next few months in
order to concentrate on pharmaceuticals.
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
The difficulties facing Lonza came into clear focus today as the
company published its half-year results, with sales down across its
custom manufacturing, organic chemicals and polymers businesses.
Chemical major BASF has expanded the range of products it offers to
pharmaceutical clients with the $65 million (€58m) purchase of
Callery Chemical from Mine Safety Appliances.
Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic
production.
Danish pharmaceutical companies increased their sales to overseas
countries by 20 per cent in the first four months of this year
compared with the same period of 2002, according to Invest In
Denmark.
Chiron's has completed its acquisition of UK vaccine and drug
delivery specialist PowderJect, making it the second-largest
manufacturer of flu vaccines worldwide.
Caliper Technologies has been given the go-ahead by the US federal
Trade Commission for its $71 million cash and stock acquisition of
Zymark, a specialist in laboratory automation and robotics
equipment.
DSM has taken a 25 per cent interest in Nijmegen, Netherlands-based
Chiralix in move which both expands DSM's capabilities in
early-stage drug development and Chiralix' position in
stereochemistry
There is a growing trend towards patients self-medicating with
over-the-counter products rather than asking their doctors for a
prescription medication, and this promises to benefit companies
involved in pharmaceutical packaging,...
Applied chemistry company Solutia has completed the latest phase of
a new containment facility to support the supply of highly potent
active pharmaceutical ingredients
GeneMedix and Penang Development of Malaysia have signed a letter
of intent that will see the two establish a new company in the
latter country's second city, at a cost of $34 million (€29m), for
the development, manufacture...
Solvents are defined as organic chemicals that are used to dissolve components. They are used during the manufacture of drug substances and can also potentially...
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...